Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HULC: Mesenchymal Stromal Cells for BPD in Preterm Infants
NCT04255147Phase 1Active, not recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Oct 2022
- Primary completion
- Nov 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of allogeneic umbilical cord tissue-derived mesenchymal stromal cells in bronchopulmonary dysplasia (BPD), sponsored by Ottawa Hospital Research Institute. Primary endpoint: Dose Limiting Toxicity at 1 week. Started Oct 2022; status: active, not recruiting.
02
Drugs
allogeneic umbilical cord tissue-derived mesenchymal stromal cells
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT04255147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04255147.